Bladder transitional cell carcinoma
Not recruitingStudy on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment
Study on the Effectiveness of Durvalumab and BCG in Treating High-Risk, Non-Muscle Invasive Bladder Cancer in Patients New to BCG Treatment
- Disease:Bladder transitional cell carcinoma
- Substances:DurvalumabInfliximab+1
Poland- Participants:18–64 years · 65+ years · Healthy volunteers
- Substances:Durvalumab
- Sponsor:AstraZeneca AB












